D
David H. Johnson
Researcher at University of Texas Southwestern Medical Center
Publications - 493
Citations - 58683
David H. Johnson is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 103, co-authored 488 publications receiving 55925 citations. Previous affiliations of David H. Johnson include Vanderbilt University & Eastern Cooperative Oncology Group.
Papers
More filters
Journal ArticleDOI
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan B. Sandler,Robert Gray,Michael C. Perry,Julie R. Brahmer,Joan H. Schiller,Afshin Dowlati,Rogerio Lilenbaum,David H. Johnson +7 more
TL;DR: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.
Journal ArticleDOI
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H. Schiller,David P. Harrington,Chandra P. Belani,Corey J. Langer,Alan B. Sandler,James E. Krook,Junming Zhu,David H. Johnson +7 more
TL;DR: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Journal ArticleDOI
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
David H. Johnson,Louis Fehrenbacher,William Novotny,Roy S. Herbst,John Nemunaitis,David M. Jablons,Corey J. Langer,Russell F. DeVore,Jacques Gaudreault,Lisa A. Damico,Eric Holmgren,Fairooz F. Kabbinavar +11 more
TL;DR: Bvacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer.
Journal ArticleDOI
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Vincent A. Miller,Ronald B. Natale,Joan H. Schiller,Joachim von Pawel,Anna Pluzanska,Ulrich Gatzemeier,John Grous,Judith S. Ochs,Steven D. Averbuch,Michael K. Wolf,Pamela Rennie,Abderrahim Fandi,David H. Johnson +17 more
TL;DR: Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.
Journal ArticleDOI
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst,Giuseppe Giaccone,Joan H. Schiller,Ronald B. Natale,Vincent A. Miller,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Ira Oliff,James A. Reeves,Michael K. Wolf,Annetta D. Krebs,Steven D. Averbuch,Judith S. Ochs,John Grous,Abderrahim Fandi,David H. Johnson +16 more
TL;DR: This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.